Aim Colorectal cancer is a heterogeneous disease with multiple underlying genetic
mutations resulting in different phenotypes. Mutation in the v‐R af murine sarcoma viral …

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
(mAbs), cetuximab and panitumumab has expanded the range of treatment options for …

Objective: To determine the impact of RAS mutation status on survival and patterns of
recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) …

Purpose: Vemurafenib, a selective inhibitor of BRAFV600, has shown significant activity in
BRAFV600 melanoma but not in less than 10% of metastatic BRAFV600 colorectal cancers …

BACKGROUND Molecular biomarkers offer the potential for refining prognostic determinants
in patients undergoing cancer surgery. Among patients with colorectal cancer, KRAS and …

Purpose: To study the somatic molecular profile of the EGF receptor (EGFR) pathway in
advanced colorectal cancer, its relationship to prognosis, the site of the primary and …

Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular
profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype …

Aims The presence of a BRAF mutation is a strong marker for poor prognosis of colorectal
carcinoma (CRC), and can be used as evidence of a sporadic mechanism of mismatch …

Background & Aims Colorectal tumors have a large degree of molecular heterogeneity.
Three integrated pathways of carcinogenesis (ie, traditional, alternate, and serrated) have …

Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …